Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.


GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc > AGM
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(47)
•••
Comment by DIYGuyon Dec 16, 2017 12:25pm
71 Views
Post# 27171242

RE:RE:RE:RE:RE:AGM

RE:RE:RE:RE:RE:AGMWe are at a 10 year low and been hovering around the latest financing price for about 4 months now. It’s a little reassuring to know the former CEO is still “all in”.

It makes sense if we have good news flow coming to not release it into the tax loss selling. Most of the weak hands must be almost out by now. Need the gynaecolical results then cohort 2 in the HNSCC trial and maybe the IND filing for COTI 219.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities